Inhaled Therapy in Respiratory Disease Market to Grow USD 16.22 Billion by 2034

The global inhaled therapy in respiratory disease market size was valued at USD 11.58 billion in 2024 and is predicted to hit around USD 16.22 billion by 2034, rising at a 3.44% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.

Ottawa, Nov. 27, 2025 (GLOBE NEWSWIRE) — The global inhaled therapy in respiratory disease market size is calculated at USD 11.98 billion in 2025 and is expected to reach around USD 16.22 billion by 2034, growing at a CAGR of 3.44% for the forecasted period.

The rise of digital health tools for monitoring and compliance, the development of advanced nebulisers (vibrating mesh and ultrasonic), and the growing use of biologics for home-based treatment drive the growth of the market.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/6307

Key Takeaways

• North America held approximately a 42% share of the global inhaled therapy in respiratory disease market in 2024.
• Asia Pacific is expected to be the fastest-growing region during the forecast period.
• By drug class/therapy type, the short-acting & long-acting bronchodilators segment held an approximate 28% share in the market in 2024.
• By drug class/therapy type, the inhaled biologics & nucleic-acid therapies segment is expected to be the fastest growing during the forecast period.
• By delivery device type, the metered-dose inhalers (MDI) segment held approximately a 35% share in the inhaled therapy in respiratory disease market in 2024.
• By delivery device type, the smart/digital inhaler add-ons & connected devices segment is expected to be the fastest growing during the forecast period.
• By indication/clinical use type, the COPD segment held an approximate 38% share in the market in 2024.
• By indication/clinical use type, the acute respiratory infections/hospital-administered inhaled therapies segment is expected to be the fastest growing during the forecast period.
• By end user/distribution channel type, the retail/outpatient pharmacies (prescription & OTC) segment held an approximate 60% share in the global inhaled therapy in respiratory disease market in 2024.
• By end user/distribution channel type, the home care & long-term care segment is expected to be the fastest growing during the forecast period.

Market Overview & Potential

What is the Growth Potential Responsible for The Growth of The Inhaled Therapy in the Respiratory Disease Market?

The main drivers for inhaled therapy in the respiratory disease market are the rising prevalence of respiratory illnesses like asthma and COPD, fueled by factors such as ageing populations, increasing air pollution, and tobacco use. Additionally, technological advancements like smart inhalers and portable nebulisers, a greater emphasis on home healthcare, and the demand for convenient, portable, and effective delivery methods are also contributing to market growth.

Quick Facts Table

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What Are the Growing Trends Associated with the Inhaled Therapy in the Respiratory Disease Market?

Smart inhalers: Networked “smart” inhalers that track usage, monitor compliance, and provide reminders are a significant trend, enhancing treatment effectiveness and patient adherence.

Advanced nebulisers: Technologies like vibrating mesh and ultrasonic nebulisers are gaining traction due to their improved efficiency, portability, and reduced treatment time.

Growing use of biologics: Biologics and monoclonal antibodies are becoming more popular for home-based treatment of asthma and COPD, with some being available in self-administered subcutaneous versions.

Product formulation: Dry powder inhalers have the largest market share among drug formulations and are expected to continue growing at the fastest rate.

Patient-centric devices: There is a growing demand for patient-friendly and portable devices that allow for easier and more convenient treatment, supporting home-based care.

What Is the Growing Challenge in the Inhaled Therapy in Respiratory Disease Market?

Challenges in the inhaled therapy market include technical difficulties in drug formulation and delivery to the lungs, physiological barriers like mucus and airway narrowing, and patient-related issues such as poor inhaler technique and adherence. Additionally, the market faces regulatory hurdles and high costs associated with development and ensuring proper device usage.

Regional Analysis

How Did North America Dominate the Inhaled Therapy in Respiratory Disease Market in 2024?

North America held approximately a 42% share of the global inhaled therapy in respiratory disease market in 2024. The North American market for inhaled therapy in respiratory diseases is the largest globally, driven by a high prevalence of conditions like asthma and COPD, strong healthcare infrastructure, and favourable reimbursement policies. Key growth drivers include technological advancements like AI-enabled and smart inhalers, increasing patient awareness, and government initiatives promoting eco-friendly inhalers.

What Made the Asia Pacific Significantly Grow in The Inhaled Therapy in Respiratory Disease Market In 2024?

Asia Pacific is expected to be the fastest-growing region during the forecast period. The Asia-Pacific inhaled therapy for respiratory diseases market is expected to grow rapidly due to high rates of respiratory illnesses like asthma and COPD, driven by factors such as increasing air pollution and a growing ageing population. Key drivers include government initiatives to improve healthcare access, rapid urbanisation, and the growing adoption of telemedicine, which is also expanding access to inhalers and related monitoring solutions.

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

Segmental Insights

By Drug Class/Therapy Type,

The short-acting & long-acting bronchodilators segment held an approximate 28% share in the market in 2024. Short-acting and long-acting bronchodilators and corticosteroids remain the backbone of inhaled respiratory care, widely used for rapid symptom relief and long-term disease control. Their demand is sustained by the high global burden of asthma and COPD and continuous formulation improvements that enhance lung deposition and patient adherence.

The inhaled biologics & nucleic-acid therapies segment is expected to be the fastest-growing during the forecast period. Inhaled biologics and nucleic acid therapies represent the next wave of precision respiratory medicine, targeting inflammatory pathways, genetic defects, and infectious agents directly in the lungs. Advancements in aerosolised delivery, stability, and targeted nanoparticles are rapidly expanding applicability in severe asthma, cystic fibrosis, and rare respiratory disorders.

By Delivery Device Type,

The metered-dose inhalers (MDI) segment held approximately a 35% share in the inhaled therapy in the respiratory disease market in 2024. MDIs remain one of the most widely used inhalation devices due to ease of use, portability, and broad drug compatibility. Growth is also supported by the shift toward low-global-warming-potential propellants and improved formulation technologies that enhance dose consistency and environmental compliance.

The smart/digital inhaler add-ons & connected devices segment is expected to be the fastest-growing during the forecast period. Smart inhalers and digital add-ons integrate sensors and connectivity to track usage patterns, monitor adherence, and support remote disease management. These devices are increasingly adopted in chronic respiratory care, enabling personalised monitoring and improving treatment outcomes through real-time data integration with clinical platforms.

By Indication/Clinical Use Type,

The COPD segment held an approximate 38% share in the market in 2024. COPD accounts for the largest share due to its chronic progression and high global patient population, requiring maintenance therapy with long-acting bronchodilators and combination inhaled regimens. Rising hospitalisations and emphasis on early intervention further drive uptake of advanced inhaled formulations and digital adherence tools.

The acute respiratory infections/hospital-administered inhaled therapies segment is expected to be the fastest-growing during the forecast period. Hospital-administered inhaled therapies for acute respiratory infections include nebulised antivirals, antibiotics, and mucolytics used in emergency and critical care. Demand is influenced by seasonal infection peaks, antimicrobial stewardship programs, and broader interest in aerosolised therapies for rapid pulmonary drug delivery.

By End User/Distribution Channel Type,

The retail/outpatient pharmacies (prescription & OTC) segment held an approximate 60% share in the global inhaled therapy in respiratory disease market in 2024. Retail and outpatient pharmacies dominate distribution due to high prescription volumes for chronic respiratory diseases and growing availability of OTC inhaled relievers. Convenience, refill adherence programs, and pharmacist-led patient education further strengthen this channel’s market role.

The home care & long-term care segment is expected to be the fastest-growing during the forecast period. Home care and long-term care segments are expanding as chronic respiratory patients shift toward home-based disease management supported by portable inhalers, nebulisers, and digital monitoring solutions. Ageing populations and healthcare system cost-reduction initiatives accelerate the adoption of remote inhaled therapy management.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

 Latest Advancements in the Market

Recent Developments

• In September 2025, novel nebulized antibiotic therapy was developed by a Hyderabad startup for the treatment of pneumonia. This development was supported by the Technology Development Board (TDB) under the Department of Science and Technology, Government of India.
• In April 2025, Aspiro Therapeutics was established by Tech Launch Arizona. It is a biotech startup that will be focusing on developing innovative inhaled therapy for chronic obstructive pulmonary disease (COPD)and asthma.

Market Value Chain Analysis

R&D

The development of highly efficient drug delivery systems through advancements in device engineering and nanotechnology to enhance the therapeutic outcomes and reduce the side effects by providing targeted and optimal lung deposition of the drugs is the focus of R&D for inhaled therapy in respiratory diseases.

Key Players: GlaxoSmithKline, AstraZeneca, Teva Pharmaceutical, and Boehringer Ingelheim.

Clinical Trials and Regulatory Approvals

The confirmation of the therapeutic equivalence, safety, and efficacy of drug formulation and specific delivery device is the main focus in the clinical trials and regulatory approval of the inhalation therapy in respiratory diseases.

Key Players: GlaxoSmithKline, AstraZeneca, Teva Pharmaceutical, and Boehringer Ingelheim.

Patient Support and Services

The patient support and services for inhaled therapy in respiratory diseases consist of personalized programs like pulmonary rehabilitation, continuous monitoring and adherence with the diagnostic health tool and telehealth, and comprehensive education for patients in inhaler techniques.

Key Players: GlaxoSmithKline, AstraZeneca, Teva Pharmaceutical, and Boehringer Ingelheim.

Top vendors and Their Offerings

• GlaxoSmithKline (GSK): The company has launched products such as Anoro Ellipta, Benlysta, Benlysta, Flixotide/Flovent, Nucala, Relvar/Breo Ellipta, Seretide/Advair, Trelegy Ellipta, and Ventolin.
• AstraZeneca: Products like Saphnelo, TULIP 1 & TULIP 2 AZALEA, Tezspire, NAVIGATOR DIRECTION, tozorakimab OBERON TITANIA PROSPERO MIRANDA, and tozorakimab TILIA are developed by the company and are in phase 3 clinical trials.
• Boehringer Ingelheim: Products such as Atrovent, Berodual, Berotec, Combivent, Respimat, Spiriva, Spiolto, and Striverdi are launched by the company.
• Cipla: The company has launched products such as Synchrobreath, Seroflo Autohaler, Triohale, Duonase, Tiova pMDI, and Transparent Rotahaler.
• Roche/Genentech: The company has contributed to the market with the launch of products like Pulmozyme (dornase alfa).

Inhaled Therapy in Respiratory Disease Market Key Players List

• Chiesi Farmaceutici
• Teva Pharmaceutical/ProAir Digihaler
• Novartis
• Viatris/Mylan
• Insmed
• Vertex Pharmaceuticals
• PARI GmbH
• Philips Respironics
• Omron Healthcare
• Aptar Pharma
• Nemera
• Vectura Group/specialist inhalation formulators
• Propeller Health (part of ResMed)
• Adherium
• Catalent/Lonza (CDMO partners)

Browse More Insights of Towards Healthcare:

The global respiratory disease vaccine market size is calculated at USD 65.72 billion in 2025, grew to USD 68.43 billion in 2026, and is projected to reach around USD 98.41 billion by 2035. The market is expanding at a CAGR of 4.12% between 2026 and 2035.

The respiratory drugs market size is forecast to grow at a CAGR of 5.8%, from USD 18.55 billion in 2025 to USD 30.81 billion by 2034, over the forecast period from 2025 to 2034.

The respiratory devices market is anticipated to grow from USD 26.57 billion in 2025 to USD 56.48 billion by 2034, with a compound annual growth rate (CAGR) of 8.74% during the forecast period from 2025 to 2034.

The global lung disease therapeutics market size is projected to reach USD 165.17 billion by 2034, growing from USD 96.94 billion in 2025, at a CAGR of 6.1% during the forecast period from 2025 to 2034.

The global ankylosing spondylitis market size is calculated at USD 6.7 billion in 2025, grew to USD 7.09 billion in 2026, and is projected to reach around USD 11.83 billion by 2035. The market is expanding at a CAGR of 5.85% between 2026 and 2035.

The U.S. clinical trials market size is calculated at US$ 43.45 in 2025, grew to US$ 46.21 billion in 2026, and is projected to reach around US$ 80.42 billion by 2035. The market is expanding at a CAGR of 6.35% between 2026 and 2035.

The oncolytic virus CDMO services market size reached US$ 419.51 million in 2025 and is anticipate to increase to US$ 483.49 million in 2026. By 2035, the market is forecasted to achieve a value of around US$ 1734.41 million, growing at a CAGR of 15.25%.

The modified antibody market size recorded US$ 3.10 billion in 2025, set to grow to US$ 3.38 billion in 2026 and projected to hit nearly US$ 7.36 billion by 2035, with a CAGR of 9.04% throughout the forecast timeline from 2026 to 2035.

The asthma and COPD medicines market size was valued at US$ 13.10 billion in 2025 and is projected to grow to 13.62 billion in 2026. Forecasts suggest it will reach approximately US$ 19.32 billion by 2035, registering a CAGR of 3.96% during the period.

The global cell & gene therapy logistics market size is estimated at US$ 6.41 billion in 2025, is projected to grow to US$ 7.76 billion in 2026, and is expected to reach around US$ 43.14 billion by 2035. The market is projected to expand at a CAGR of 21% between 2026 and 2035.

Segments Covered in The Report

By Drug Class/Therapy Type

• Short-acting & Long-acting Bronchodilators (SABA/LABA/SAMA/LAMA)
• SABA (short-acting β2 agonists)
• LABA (long-acting β2 agonists)
• SAMA/LAMA (antimuscarinics/long-acting muscarinic antagonists)
• Inhaled Corticosteroids (ICS)
• Combination Inhalers (ICS/LABA, LABA/LAMA, ICS/LABA/LAMA)
• Nebulized Antibiotics & Antimicrobials (e.g., tobramycin, liposomal aminoglycosides)
• Mucolytics & Enzymatic Therapies (e.g., dornase alfa)
• Inhaled Biologics & Nucleic-Acid Therapies
• Inhaled monoclonal antibodies, inhaled peptides, inhaled RNA/DNA therapeutics
• Supportive/Rescue Therapies & Others (bronchodilator combos, adjuncts)

 By Delivery Device Type

• Metered-Dose Inhalers (MDI)
• pressurised MDIs (pMDI) with propellants
• digital/M2M-enabled MDIs (dose counters, sensors)
• Dry Powder Inhalers (DPI)
• single-dose, multi-dose reservoirs/cartridges
• Nebulizers
• jet nebulisers, ultrasonic, mesh nebulisers
• Soft-Mist Inhalers (SMI)
• Smart/Digital Inhaler Add-ons & Connected Devices
• integrated sensors, adherence platforms, data analytics

By Indication/Clinical Use 

• COPD
• Asthma
• Cystic Fibrosis
• Bronchiectasis & NTM/Chronic Pulmonary Infections
• Pulmonary Hypertension & Other Niche Indications
• Acute Respiratory Infections/Hospital-administered inhaled therapies

By End User/Distribution Channel

• Retail/Outpatient Pharmacies (Prescription & OTC)
• Hospitals & Acute Care Settings
• Homecare & Long-term Care
• E-commerce/Online Pharmacies & Direct-to-Patient

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/6307

Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.